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Background: Medulloblastoma is a malignant, invasive embryonal tumor of the cerebellum and accounts for 20%
of intracranial tumors in children. QSOX1, whose functions include formation of disulphide bridges, which are
needed for correct protein folding and stability, formation of the extracellular matrix, regulation of the redox status
and cell cycle control, appears to be involved in apoptosis in pathological states such as cancer. Thus, the aim of
this study was to investigate the immunohistochemical expression of QSOX1 in medulloblastomas and
nonneoplastic cerebellum.
Methods: Histology blocks of pediatric medulloblastomas were separated and two representative areas of the
tumors and non-neoplastic cerebellum samples were used to construct tissue microarrays (TMAs) that were stained
with an anti-QSOX1 antibody, and the slides were read using image analysis software.
Results: QSOX1 immunoexpression was observed in the non-neoplastic cerebellum samples and the medulloblastoma
samples. There was no statistically significant relationship between QSOX1 immunopositivity in the medulloblastoma
samples and the clinical and pathological variables.
Conclusions: Although QSOX1 did not prove useful for stratifying patients into risk groups, tumor cells and the fibrillar
extracellular matrix were positive for this marker, indicating that this enzyme may be involved in the pathogenesis
of medulloblastoma.
Virtual Slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1822040654139436
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Medulloblastoma is a malignant embryonal tumor of the
nervous system. It has histological features reminiscent
of a neuroepithelial tumor and consists of small round
blue cells embedded in a glial extracellular matrix (ECM),
or neuropile.
During the last decade, new discoveries in molecular
biology have shown that stratification of embryonal tu-
mors into risk groups based only on histological and
clinical criteria is of limited. Specific genetic mutations
should also be investigated, as these are very often char-
acteristic of more aggressive tumors [1]. Furthermore, in* Correspondence: lnno@terra.com.br
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unless otherwise stated.spite of the new surgical and chemotherapeutic tech-
niques continually proposed for embryonal tumors, the
prognosis for medulloblastoma remains poor. Patients
initially considered low-risk may relapse and behave like
high-risk patients. In light of this, various studies of em-
bryonal tumors have also used new biomarkers that strat-
ify these tumors into more accurate prognostic groups.
QSOX1 belongs to a family of proteins initially de-
scribed in the reproductive system of male rodents and
involved in the formation of disulphide bridges, which
are needed for the correct folding and functioning of
proteins responsible for the formation of the ECM,
growth control, apoptosis and cell signaling [2]. It plays
an important role in the induction of apoptosis in re-
sponse to stress-inducing events, in mesenchymal cellThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Descriptive statistics for the clinical variables in
the group of patients with medulloblastoma
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cially in nerve tissue. In view of this, as medulloblasto-
mas are made up of embryonic cells and maturation
may be related to a better prognosis for these tumors,
expression of QSOX1 in medulloblastomas would be ex-
pected to be related to better biological behavior. In
addition, expression of QSOX1 may be related to better
response to chemotherapy because of its role in the in-
duction of apoptosis in response to stress-inducing
events [3,4]. This study reports immunohistochemical
expression of QSOX1 in medulloblastomas and human
cerebellum, the former for the first time.
Methods
Patients and tissue specimens
Twenty nine medulloblastoma samples from the anatomic
pathology service at the Pequeno Príncipe Children’s
Hospital taken from patients with their diagnosis confirmed
between 1998 and 2009 were used. The study was approved
by the research ethics committees at the Pontifical Catholic
University of Paraná and the Pequeno Príncipe Hospital
(number 0518–07).
Immunohistochemistry
Histological slides stained with hematoxylin-eosin were
reviewed, and the samples classified according to their
histological type. Two representative samples of each
tumor (fifty-eight cores) and twelve samples/cores of
non-neoplastic cerebellum were selected and used to
prepare five tissue microarrays (TMAs) [5].
Histological sections were cut from these blocks and
incubated with mouse anti-human-QSOX1 recombinant
monoclonal antibody produced at the Federal University
of Paraná (UFPR) [3,6]. AdvanceTM HRP Dako® was used
as the secondary antibody. The immune reactions were
developed by adding DAB chromogen-substrate solution
(Dako®) to the slides.
Evaluation of immunoreactivity
Immunohistochemical expression of QSOX1 was evalu-
ated using the morphometric and color functions in
Image Proplus® image processing and analysis software
running on a Dell® computer coupled to a Dino Eye® cam-
era and an Olympus BX40 microscope. A sample of nor-
mal cerebellum was used as a reference against which the
immunohistochemical expression of the anti-QSOX1 anti-
body could be evaluated. Immunopositive areas in a 400x
high-power field of this cerebellum sample were input in
the Image Proplus® software, which stores them as a mask.
The mean immunopositive area per high-power field in
the medulloblastomas was calculated using four images
for each sample taken with a 40x objective. The image
from a normal cerebellum (the mask) was superimposed
on each of these images using the Image Proplus®software, which identifies those areas where the staining is
similar to that in the mask, i.e., immunopositive areas, and
calculates the mean total immunopositive area per high-
power field in mm2.
The following clinical data were obtained from the
twenty nine patients’ medical records: age at diagnosis;
risk group; type of surgical resection (whether complete
or not); whether there were tumor relapses after surgery;
how long after surgery these relapses occurred; presence
or otherwise of metastases at diagnosis; use or otherwise
of post-surgery adjuvant chemotherapy; whether the pa-
tient died after the treatment; and how long after surgery
death occurred. Patients were followed up for between 2
and 12 years.
The variables were tested for normality with the
Kolmogorov-Smirnov test. The non-parametric Mann–
Whitney test was used to compare quantitative variables
between the various groups. The significance level was set
at p < 0.05. The data were analyzed with Statistica 8.0.
Results
Mean age at diagnosis of the 29 patients in the study
was 4.8 years (1 month to 15 years). Nineteen patients
were three years or older, and twenty were high risk, i.e.,
they were under three years of age and/or had a residual
tumor after surgery and/or metastases were present at
Table 2 Relationship between mean immunohistochemical
expression of QSOX1 in medulloblastomas and total
surgical resection, post-surgery relapse, death, age at




Mean Median p value**
Death Yes 0.013 0.012
No 0.012 0.013 0.635
Age at diagnosis <3 years 0.013 0.013
≥3 years 0.013 0.012 0.131
Total surgical resection Yes 0.013 0.012
No 0.012 0.012 0.981
Post-surgery relapse Yes 0.012 0.012
No 0.013 0.012 0.481
Risk group Low 0.014 0.012
High 0.013 0.013 0.738
*QSOX1-immunopositive area (mm2); **Mann–Whitney test (p value < 0.05).
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ommended in the literature. After the surgery, 15 still had
residual lesions. None of the patients presented with me-
tastases at diagnosis. Post-surgery relapses were observed
in nine patients and occurred 1.7 years after surgery on
average. Twenty-six patients needed post-surgery chemo-
therapy. Three of the 29 patients died; the average time
between diagnosis and death was 32.7 days (Table 1).
Twenty-eight (96.6%) of the medulloblastomas were clas-
sic and one (3.4%) desmoplastic. Mean QSOX1 immu-
noexpression in all the medulloblastomas was 0.0135 mm2.
Median QSOX1 immunoexpression was analyzed for cor-
relation with the clinical variables (age; whether under or
over three years of age; high or low risk; total or incom-
plete resection; presence of post-surgery relapses; use of
post-surgery chemotherapy; and death). The results are
shown in Table 2.Figure 1 Immunoexpression of QSOX1 in tumor-free cerebellum and in a
B. Immunopositivity of the medulloblastoma X200.Analysis of normal cerebellar tissue revealed positive
staining for QSOX1 in the fibrillar matrix and Purkinje
cells and an absence of staining in granule cells (Figure 1).
In samples of classic medulloblastomas (N = 28), the
fibrillar matrix (neuropile) exhibited intense, diffuse
staining. Similar staining was also occasionally observed
in the cytoplasm of neoplastic cells, particularly in the
perinuclear region. QSOX1 immunohistochemical stain-
ing in desmoplastic medulloblastomas (N = 1) was similar
to that observed in classic medulloblastomas. Although
positivity in the matrix in the former was greater, this can
be explained by the greater abundance of matrix in this
type of tumor.
Discussions
Although the role of sulfhydryl oxidases has not been
fully elucidated, an understanding of their potential sub-
strates and functions can be gained from their cellular
distribution [7]. The extracellular location of QSOX1
suggests that it may be involved in cell signaling or ECM
remodeling [8]. QSOX1 is also found in the intracellular
environment in various organelles, especially in the
endoplasmic reticulum and Golgi complex [8-10].
The sulfhydryl oxidase QSOX1 is expressed in various
human tissues, such as those from the myocardium, pla-
centa, stomach, lung, liver, brain, kidney, skeletal muscle
and pancreas [3,11].
QSOX1 has been found in the Golgi complex, suggest-
ing that one of its main functions is to act in the extra-
cellular compartment [8,12-14]. Although in humans
QSOX1 has been described in both the Golgi complex
and endoplasmic reticulum, the fact that it has been
found in the Golgi complex in the central nervous sys-
tem of mice suggests that it is involved in maintenance
of the ECM [14].
This oxidase is involved in the formation of disulphide
bridges in certain proteins that are responsible for the
formation of the ECM [8,12,13,15], which in turn plays amedulloblastoma. A. Immunopositivity of Purkinje cells X400.
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QSOX1 has a role in ECM-cell interactions, it may in-
duce apoptosis [11].
The interest in studying QSOX1 expression in the cen-
tral nervous system arose because of the role this enzyme
plays in maintaining the redox state, which may be related
to neuronal death [8,12,13]. Expression of QSOX1 has
been detected in the neuronal Golgi apparatus in mice,
particularly in the cerebellum, where it was observed in
cerebellar neurons in deep nuclei and the cerebellar cortex
and was most intense in dentate, globose, emboliform and
fastigial nuclei [16]. In the same study, Purkinje cells and
granule cells in the cerebellar cortex did not stain, unlike
the Golgi cells in the granular layer, particularly those in
contact with Purkinje cells [16].
The existence of QSOX1 in neuronal bodies that se-
crete neuropeptides may indicate that this enzyme also
has intracellular functions. QSOX1 has also been found
in mouse fetuses, highlighting the role it plays during
the development of the nervous system, when it may be
involved in neuronal migration and maturation [16].
Studies of QSOX1 expression during embryonic devel-
opment of the mouse nervous system found that Purkinje
cells express QSOX1 temporarily during the neuronal mat-
uration phase of the postnatal period, when dendritic pro-
cesses grow and remodel, synapses form and there is
interaction with glial processes [16].
The immunopositivity observed in the fibrillar matrix
and Purkinje cell bodies in non-neoplastic cerebellum
samples from children with medulloblastoma may reflect
the role of this protein in the developing and maturing
cerebellum. Positive staining for QSOX1 in the fibrillar
matrix and cytoplasm of medulloblastoma cells suggests
that this enzyme is involved in the formation of the
ECM in these tumors, while the positive staining ob-
served in the perinuclear region of medulloblastoma
cells may be related to the fact that QSOX1 is found in
the Golgi complex.
The present study has limitations that need to be
clearly discussed. The fewer number of blocks with me-
dulloblastoma could be considered a limitation. How-
ever, this number eventually becomes significant because
the number of patients with problem is small. The ori-
ginal observation of the impact of presence of QSOX-1
on patient in the present study can provide information
for future studies.
Conclusions
QSOX1 is detected in human cerebellar tissue and me-
dulloblastoma samples; however, determining expression
of this enzyme does not help in the identification of risk
groups as it does not appear to be associated with a
worse prognosis. The immunohistochemical expression
of this enzyme reported here reinforces the findings ofprevious studies using animal models and highlights the
need for further studies into the role of this enzyme in
the pathogenesis of medulloblastoma.
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